Erythropoietin News and Research

RSS

Erythropoietin, or its alternative erythropoetin or EPO, is a glycoprotein hormone that controls erythropoiesis, or red blood cell production. It is a cytokine for erythrocyte (red blood cell) precursors in the bone marrow.

3SBio's first-quarter 2010 total net revenues up 40.5%

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the first quarter ended March 31, 2010.

17 May 2010

Merck hosts R&D and Business Briefing

Merck & Co., Inc. today hosted its first R&D and Business Briefing since the completion of the Merck and Schering-Plough merger. The event included a comprehensive review of the company's late-stage pipeline, as well as the company's commercial strategy and progress made in the integration of Merck's worldwide operations.

12 May 2010

Implementation of quality improvement intervention reduces medication use in premature babies: Study

A new study by Pediatrix Medical Group researchers has found that the implementation of a quality improvement intervention significantly reduces the use of a large number of medications in premature babies across a broad neonatal intensive care network.

3 May 2010

Affymax institutes quiet period in connection with Hematide Phase 3 result analysis

Affymax, Inc. today announced that it has instituted a quiet period to curtail discussions with the investor community and the media in connection with the analysis of Phase 3 results for the investigational drug, Hematide, in four clinical trials (PEARL 1, PEARL 2, EMERALD 1 and EMERALD 2) which evaluated Hematide for the treatment of anemia in chronic renal failure patients.

23 Apr 2010

Data from Phase 2 clinical trials of Hematide/peginesatide presented at NKF Annual Meeting

Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced data from several post hoc analyses of Phase 2 clinical trials that evaluated Hematide/peginesatide in dialysis patients with anemia in chronic kidney disease. The data provide hypotheses for further investigation of this agent in anemia management in this patient population.

16 Apr 2010

Lotus Pharmaceuticals reports EBIT increase of 29% in 2009

Lotus Pharmaceuticals, Inc., a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China (the "PRC") reported that its 2009 net earnings were approximately $16.4 million, or $0.33 per diluted share, compared with approximately $12.8 million, or $0.27 per diluted share, in 2008. Net revenues were approximately $57.8 million in 2009 compared with $73.8 million in 2008.

1 Apr 2010

NKF 2010 Spring Clinical Meeting: Multiple posters on Hematide/peginesatide to be presented

Affymax, Inc. and Takeda Pharmaceuticals Global Research & Development Center, Inc., U.S., today announced multiple posters on Hematide™/peginesatide have been accepted for presentation at the National Kidney Foundation (NKF) 2010 Spring Clinical Meeting taking place April 13-17, 2010 in Orlando, Florida. Hematide is an investigational agent for the treatment of anemia in chronic renal failure (also referred to as renal anemia).

31 Mar 2010

Clinical research trial of new treatment to restore brain cells damaged by stroke passes safety stage

A clinical research trial of a new treatment to restore brain cells damaged by stroke has passed an important safety stage, according to the UC Irvine neurologist who led the effort.

11 Mar 2010

Affymax initiates Phase 3 clinical testing of Hematide in Japan, receives $5M milestone payment

Affymax, Inc. today announced that it has received a $5 million development milestone payment from Takeda Pharmaceutical Company as part of the companies’ exclusive global agreement to develop and commercialize Hematide™, Affymax’s investigational drug for the treatment of anemia in chronic renal failure patients. The milestone was achieved with the initiation of Phase 3 clinical testing of Hematide to treat anemia in chronic renal failure patients in Japan.

10 Mar 2010

Growing human therapeutic proteins in algae can help reduce cancer treatment cost

Pharmaceutical companies could substantially reduce the expense of costly treatments for cancer and other diseases produced from mammalian or bacterial cells by growing these human therapeutic proteins in algae-rapidly growing aquatic plant cells that have recently gained attention for their ability to produce biofuels.

9 Mar 2010

Aggressive treatment of anemia with ESAs may lower risk of death for dialysis patients: Study

Aggressive treatment of anemia with intravenous iron and drugs known as erythropoiesis-stimulating agents (ESAs) may lower the risk of death for dialysis patients with severe anemia - but also may increase the risk of death among patients with milder anemia, a new study led by a University of North Carolina at Chapel Hill epidemiologist suggests.

3 Mar 2010

FDA approves risk management program on ESA's for treating anemia due to chemotherapy

The U.S. Food and Drug Administration today approved a risk management program to inform healthcare providers and their patients about the risks of a class of drugs called Erythropoiesis-Stimulating Agents (ESAs). For patients with cancer, the program is also designed to help ensure the appropriate administration of these drugs, which they receive to treat anemia that can occur as a result of chemotherapy.

17 Feb 2010

New ICD-9-CM database provides FDA-approved and off-label uses for therapeutic drugs

A recently released Drug Diagnosis Coding database from RJ Health Systems provides accurate FDA-approved and Compendia-listed off-label uses for therapeutic classes such as Oncology, Anti-Emetics, Erythropoietin Stimulating Agents and Multiple Sclerosis Agents. The

5 Feb 2010

PROLOR Biotech reports the EC approval of Merck's ELONVA

PROLOR Biotech, Inc., (OTC Bulletin Board: PBTH) today noted the European Commission (EC) approval of Merck & Co., Inc.'s ELONVA®, a long-acting CTP-modified version of the fertility drug follicle stimulating hormone (FSH).

30 Jan 2010

Medco Health Solutions launches Medco TRC for oncology patients

Medco Health Solutions, Inc. today announced the launch of the Medco Therapeutic Resource Center® (TRC) for oncology patients headquartered in Whitestown, Ind., where specialist pharmacists will manage the company's more than 850,000 patients currently living with cancer, one of the fastest growing segments of healthcare.

21 Jan 2010

PROLOR Biotech's hGH-CTP Phase I study data to be presented at the BIO CEO & Investor Conference

PROLOR Biotech, Inc., today announced that final data from a randomized, dose-escalating Phase I clinical study of its longer-acting version of human growth hormone (hGH-CTP) will be featured in an oral presentation by PROLOR management at the 12th Annual BIO CEO & Investor Conference to be held at the Waldorf-Astoria Hotel in New York City on February 8-9, 2010.

20 Jan 2010

Ligand Pharmaceuticals acquires Neurogen

Ligand Pharmaceuticals Incorporated announced today that it has completed the acquisition of Neurogen Corporation, following approval of the transaction by Neurogen stockholders earlier today. As a result, Ligand gains a fully funded partnership with Merck & Co., additional pipeline assets, drug discovery resources and additional cash balances.

23 Dec 2009

Amgen and Roche end EPO patent infringement dispute

Amgen announced today that the United States (U.S.) District Court in Boston has entered final judgment and a permanent injunction against Roche prohibiting Roche from infringing Amgen's patents on recombinant erythropoietin (EPO), thus bringing the five-year patent infringement dispute to an end.

23 Dec 2009

Acceleron Pharma's ACE-536 stimulates red blood cell production through novel mechanism

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, presented data demonstrating that ACE-536 promotes formation of red blood cells through inhibition of members of the TGF-beta superfamily, at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

New discoveries to treat life-threatening blood disorder presented at ASH annual meeting

A genetic variation that may indicate a patient's risk of developing a potentially life-threatening blood disorder if exposed to certain pharmaceutical therapies or chemicals is one of several medical discoveries scientists at cancer diagnostics leader Quest Diagnostics will present during the 51st American Society of Hematology (ASH) Annual Meeting and Exposition, December 5-8, 2009, in New Orleans, LA.

4 Dec 2009